Working Paper Article Version 2 This version is not peer-reviewed

Imatinib Sets Pericyte Mosaic in the Retina

Version 1 : Received: 30 December 2019 / Approved: 2 January 2020 / Online: 2 January 2020 (04:33:47 CET)
Version 2 : Received: 26 February 2020 / Approved: 29 February 2020 / Online: 29 February 2020 (11:17:52 CET)

How to cite: Kovács-Öller, T.; Ivanova, E.; Szarka, G.; Tengölics, Á.J.; Völgyi, B.; Sagdullaev, B.T. Imatinib Sets Pericyte Mosaic in the Retina. Preprints 2020, 2020010009 Kovács-Öller, T.; Ivanova, E.; Szarka, G.; Tengölics, Á.J.; Völgyi, B.; Sagdullaev, B.T. Imatinib Sets Pericyte Mosaic in the Retina. Preprints 2020, 2020010009

Abstract

The nervous system demands an adequate oxygen and metabolite exchange, making pericytes (PCs), the only vasoactive cells on the capillaries, essential to neural function. Loss of PCs is a hallmark of multiple diseases, including diabetes, Alzheimer’s, amyotrophic lateral sclerosis (ALS) and Parkinson’s. Platelet-Derived Growth Factor Receptors (PDGFRs) have been shown to be critical to the PC function and survival. However, how PDGFR-mediated PC activity affects vascular homeostasis is not fully understood. Here, we tested the hypothesis that imatinib, a chemotherapeutic agent and a potent PDGFR inhibitor, alters the PC distribution and thus induces vascular atrophy. We performed a morphometric analysis of the vascular elements in sham control and imatinib-treated NG2-DsRed mice. Vascular morphology and the integrity of the blood-retina barrier (BRB) were evaluated using blood albumin labeling. We found that imatinib decreased the number of PCs and blood vessel (BV) coverage in all retinal vascular layers, this was accompanied by a shrinkage of BV diameters. Surprisingly, the total length of capillaries was not altered, suggesting a preferential effect of imatinib on PCs. Furthermore, the blood-retina barrier disruption was not evident. In conclusion, our data suggest that imatinib could help in treating neurovascular diseases and serve as a model for PC loss, without BRB disruption.

Subject Areas

pericyte; retina; Imatinib; Gleevec; PDGFR; neurovascular

Comments (1)

Comment 1
Received: 29 February 2020
Commenter: Tamas Kovacs-Oller
Commenter's Conflict of Interests: Author
Comment: This is a new version of the manuscript currently under review. We added a new Sup Fig. 1.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.